NewAmsterdam Pharma Co N.V annual ebitda
2021
2022
2023
2024
2025
NewAmsterdam Pharma Co N.V EBITDA Growth & History (NAMS)
NewAmsterdam Pharma Co N.V's calculated EBITDA was −$225.5M for fiscal 2025.
View full NewAmsterdam Pharma Co N.V company overviewNewAmsterdam Pharma Co N.V annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$225.5M | −$49.3M | — |
| 2024 | 2024-12-31 | −$176.2M | $6.7M | — |
| 2023 | 2023-12-31 | −$182.9M | −$179.4M | — |
| 2022 | 2022-12-31 | −$3.5M | $31.4M | — |
| 2021 | 2021-12-31 | −$35.0M | — | — |
NewAmsterdam Pharma Co N.V quarterly ebitda
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | EBITDA | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$64.8M | −$29.2M | — |
| Q1 2026 | 2026-03-31 | −$58.4M | $10.5M | — |
| Q4 2025 | 2025-12-31 | −$66.0M | −$22.8M | — |
| Q3 2025 | 2025-09-30 | −$55.0M | −$30.1M | — |
| Q2 2025 | 2025-06-30 | −$35.5M | $17.0M | — |
| Q1 2025 | 2025-03-31 | −$68.9M | −$13.4M | — |
| Q4 2024 | 2024-12-31 | −$43.3M | $7.8M | — |
| Q3 2024 | 2024-09-30 | −$24.9M | $24.6M | — |
| Q2 2024 | 2024-06-30 | −$52.5M | −$10.0M | — |
| Q1 2024 | 2024-03-31 | −$55.5M | −$15.6M | — |
| Q4 2023 | 2023-12-31 | −$51.1M | — | — |
| Q3 2023 | 2023-09-30 | −$49.5M | — | — |
| Q2 2023 | 2023-06-30 | −$42.5M | — | — |
| Q1 2023 | 2023-03-31 | −$39.8M | — | — |
NewAmsterdam Pharma Co N.V ebitda trends
Between the periods ended 2021-12-31 and 2025-12-31, NewAmsterdam Pharma Co N.V's ebitda decreased from −$35.0M to −$225.5M, a change of −$190.5M. The latest reported quarter, Q2 2026, shows −$64.8M.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review NewAmsterdam Pharma Co N.V source filings ↗